Literature DB >> 27888357

Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma.

Samantha Kendrick1, Lisa M Rimsza2, David W Scott3, Graham W Slack4, Pedro Farinha4, King L Tan4, Daniel Persky5, Soham Puvvada5, Joseph M Connors3, Laurie Sehn3, Randy D Gascoyne3,4, Monika Schmelz6.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27888357     DOI： 10.1007/s00428-016-2041-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


× No keyword cloud information.
  19 in total

1.  Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma.

Authors:  Monika Schmelz; Santiago Montes-Moreno; Miguel Piris; Sarah T Wilkinson; Lisa M Rimsza
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

2.  A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.

Authors:  Soham D Puvvada; Hongli Li; Lisa M Rimsza; Steven H Bernstein; Richard I Fisher; Michael LeBlanc; Monika Schmelz; Betty Glinsmann-Gibson; Thomas P Miller; Anne-Marie Maddox; Jonathan W Friedberg; Sonali M Smith; Daniel O Persky
Journal:  Leuk Lymphoma       Date:  2016-01-12

Review 3.  Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach.

Authors:  Jeremy S Abramson; Margaret A Shipp
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

4.  Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.

Authors:  Lisa M Rimsza; Robin A Roberts; Elias Campo; Thomas M Grogan; Silvia Bea; Itziar Salaverria; Andreas Zettl; Andreas Rosenwald; German Ott; H Konrad Muller-Hermelink; Jan Delabie; Richard I Fisher; Joseph M Unger; Michael Leblanc; Louis M Staudt; Elaine S Jaffe; Randy D Gascoyne; Wing C Chan; Dennis D Weisenburger; Timothy Greiner; Rita M Braziel; Thomas P Miller
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

5.  Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Lisa M Rimsza; Michael L Leblanc; Joseph M Unger; Thomas P Miller; Thomas M Grogan; Daniel O Persky; Ralph R Martel; Constantine M Sabalos; Bruce Seligmann; Rita M Braziel; Elias Campo; Andreas Rosenwald; Joseph M Connors; Laurie H Sehn; Nathalie Johnson; Randy D Gascoyne
Journal:  Blood       Date:  2008-06-10       Impact factor: 22.113

6.  Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.

Authors:  Paul N Meyer; Kai Fu; Timothy C Greiner; Lynette M Smith; Jan Delabie; Randy D Gascoyne; German Ott; Andreas Rosenwald; Rita M Braziel; Elias Campo; Julie M Vose; Georg Lenz; Louis M Staudt; Wing C Chan; Dennis D Weisenburger
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

7.  Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence.

Authors:  A F List; C M Spier; T P Miller; T M Grogan
Journal:  Leukemia       Date:  1993-03       Impact factor: 11.528

8.  Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.

Authors:  Lisa M Rimsza; Robin A Roberts; Thomas P Miller; Joseph M Unger; Michael LeBlanc; Rita M Braziel; Dennis D Weisenberger; Wing C Chan; H Konrad Muller-Hermelink; Elaine S Jaffe; Randy D Gascoyne; Elias Campo; Deborah A Fuchs; Catherine M Spier; Richard I Fisher; Jan Delabie; Andreas Rosenwald; Louis M Staudt; Thomas M Grogan
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

9.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

10.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544
View more
  5 in total

1.  Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray.

Authors:  Diego Villa; King L Tan; Christian Steidl; Susana Ben-Neriah; Muntadhar Al Moosawi; Tamara N Shenkier; Joseph M Connors; Laurie H Sehn; Kerry J Savage; David W Scott; Randy D Gascoyne; Graham W Slack
Journal:  Blood Adv       Date:  2019-12-10

2.  A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.

Authors:  Daniel O Persky; Hongli Li; Lisa M Rimsza; Paul M Barr; Leslie L Popplewell; Charles L Bane; Ann Von Gehr; Michael LeBlanc; Richard I Fisher; Sonali M Smith; Jonathan W Friedberg
Journal:  Am J Hematol       Date:  2018-01-25       Impact factor: 10.047

3.  Proteomic changes in cerebrospinal fluid from primary central nervous system lymphoma patients are associated with protein ectodomain shedding.

Authors:  Uwe Schlegel; Kai Stühler; Daniel Michael Waldera-Lupa; Omid Etemad-Parishanzadeh; Mareike Brocksieper; Nina Kirchgaessler; Sabine Seidel; Thomas Kowalski; Manuel Montesinos-Rongen; Martina Deckert
Journal:  Oncotarget       Date:  2017-11-24

4.  HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?

Authors:  Marcel Nijland; Rianne N Veenstra; Lydia Visser; Chuanhui Xu; Kushi Kushekhar; Gustaaf W van Imhoff; Philip M Kluin; Anke van den Berg; Arjan Diepstra
Journal:  Oncoimmunology       Date:  2017-03-03       Impact factor: 8.110

Review 5.  Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.

Authors:  Marie de Charette; Roch Houot
Journal:  Haematologica       Date:  2018-07-13       Impact factor: 9.941
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.